Michael Gilles, MD
Gastroenterology · Reno, NVNPI 1164579025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 46.7% of the total. Reporting peaked in 2021 at $1,685 and has fallen 63.4% since, to $616 in 2025.
Across 271 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$330
- Takeda Pharmaceuticals U.S.A., Inc.$325
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$322
- Bristol Myers Squibb$282
- Sanofi$261
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,03798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $2,399 |
| Johnson & Johnson | 16 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $325 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $322 |
| Bristol Myers Squibb | 16 | $282 |
| Sanofi | 11 | $261 |
| Nestle Healthcare Nutrition Inc. | 10 | $242 |
| Pfizer | 10 | $148 |
| Olympus America Inc. | 6 | $103 |
| Ironwood Pharmaceuticals, Inc | 6 | $102 |
| Regeneron Healthcare Solutions, Inc. | 4 | $93 |
| Intercept Pharmaceuticals, Inc. | 3 | $54 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 3 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Braintree Laboratories, Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Lilly USA, LLC | 1 | $32 |
| Exact Sciences | 1 | $29 |
| Romark Laboratories, LC | 1 | $27 |
| Gilead | 1 | $25 |
| Lucid Diagnostics Inc. | 1 | $23 |
| QOL Medical, LLC | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Merck | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Shionogi Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$123
How this compares
$5,137 in reported general payments places this provider in the 60th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $95,361 |
| RinvoqUpadacitinib | 12 | $74,380 |
| XifaxanRifaximin | 14 | $48,834 |
| Mesalamine | 19 | $13,600 |
| Colestipol Hcl | 44 | $4,511 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,016 |
| Omeprazole | 192 | $2,826 |
| Sucralfate | 19 | $1,789 |
| Pantoprazole Sodium | 49 | $1,595 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 83 | $1,460 |
| Esomeprazole Magnesium | 27 | $1,299 |
| Dicyclomine Hcl | 29 | $1,232 |
| Lansoprazole | 11 | $995 |
| Budesonide DrBudesonide | 12 | $982 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 37 | $682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,399 | $74,38012 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $322 | $48,83414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Reno
- George VagujhelyiReno$10K
- Dennis YamamotoReno$10K
- Ting-Hui HsiehReno$9K
- William PfauReno$8K
- Ryan SefcikReno$7K
- Erik DejongheReno$5K
- Sam NouraniReno$3K
- Jonathan PezanoskiReno$3K
- Tom FangReno$3K
- Timothy HaltermanReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.